☆ 4.4 Article

Effects of SGLT2 inhibitors on cardiac structure and function

HEART FAILURE REVIEWS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes

Nick S. R. Lan et al.

Summary: Sodium-glucose cotransporter 2 inhibitors have shown potential to improve heart failure outcomes, but their effects on left ventricular function post-ACS in patients with type 2 diabetes were unclear. A prospective observational study found that initiating empagliflozin therapy after ACS in T2D patients was associated with favorable changes in LV diastolic function parameters, suggesting the potential benefits of adding empagliflozin to ACS therapy in this patient population.

INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

Matthias Rau et al.

Summary: Empagliflozin treatment of patients with T2D does not have significant effects on hemodynamic parameters after 1 or 3 days, nor after 3 months, but leads to rapid and sustained significant improvement of diastolic function.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

David Bode et al.

Summary: This study found that the SGLT-1&2 inhibitor sotagliflozin improved left atrial remodeling in a metabolic HFpEF rat model, reduced the occurrence of cellular arrhythmias, and enhanced mitochondrial function. These effects may be related to the inhibition of sodium-calcium exchanger (NCX) forward-mode activity.

CARDIOVASCULAR DIABETOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

William T. Abraham et al.

Summary: The two trials showed neutral primary outcomes, but hypothesis-generating improvements were observed in exploratory analyses of secondary endpoints with empagliflozin in HFrEF patients.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

Milton Packer et al.

Summary: The combination treatment of sacubitril/valsartan and empagliflozin in heart failure patients has been shown to reduce cardiovascular death or hospitalization risk, maintain stable glomerular filtration rate, and the effects are not diminished by intensive treatment.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sharmaine Thirunavukarasu et al.

Summary: The study showed that the SGLT2 inhibitor empagliflozin significantly improved cardiac energy state, reversed adverse myocardial cellular remodeling, and enhanced cardiac function in patients with type 2 diabetes. This offers therapeutic opportunities for preventing or treating heart failure in this population.

DIABETES (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

Carlos G. Santos-Gallego et al.

Summary: This study found that empagliflozin significantly improved left ventricular function and volumes, functional capacity, and quality of life in nondiabetic HFrEF patients, compared to placebo. The observations strongly support the role of sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients regardless of their glycemic status.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction A Substudy of the Empire HF Randomized Clinical Trial

Massar Omar et al.

Summary: Empagliflozin, an SGLT2 inhibitor, showed beneficial effects on cardiac remodeling in patients with heart failure and reduced ejection fraction. The drug significantly reduced left ventricular and atrial volumes without affecting ejection fraction after 12 weeks of treatment, suggesting potential benefits in managing HFrEF. Further studies are needed to explore the long-term effects of SGLT2 inhibitors beyond 12 weeks.

JAMA CARDIOLOGY (2021)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus The IDDIA Trial

Chi Young Shim et al.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Biykem Bozkurt et al.

Summary: This document proposes a universal definition of heart failure as a clinical syndrome and revised stages of HF, as well as a new classification based on left ventricular ejection fraction (LVEF) levels. The classification includes HFrEF, HFmrEF, HFpEF, and HFimpEF based on LVEF percentages.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Global longitudinal strain in heart failure with reduced ejection fraction: Prognostic relevance across disease severity as assessed by automated cluster analysis

Erberto Carluccio et al.

Summary: This study clustered HFrEF patients into different risk profiles and found that GLS can independently predict outcomes, especially for patients with non-advanced disease.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study

Satoshi Oka et al.

Summary: This study compared the efficacy of SGLT2i treatment on LV dysfunction between early and advanced DMCMP. It found that empagliflozin had more remarkable positive effects on LV dysfunction in early DMCMP than in advanced DMCMP, suggesting that early intervention with SGLT2i for DMCMP may be preferable.

BMC CARDIOVASCULAR DISORDERS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Sergio Gamaza-Chulian et al.

Summary: SGLT2 inhibitors are associated with a significant reduction in indexed left ventricular mass and an increase in longitudinal strain in patients with type 2 diabetes mellitus, potentially explaining the clinical benefits observed in trials.

BMC CARDIOVASCULAR DISORDERS (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M. Y. Lee et al.

Summary: The study confirmed the effectiveness of sodium-glucose cotransporter 2 inhibitor empagliflozin in reducing left ventricular volumes in patients with HFrEF, favoring reverse left ventricular remodeling. This may be one of the mechanisms by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Biykem Bozkurt et al.

Summary: This document proposes a universal definition, revised stages, and new classification of heart failure based on left ventricular ejection fraction. The classification includes HF with reduced, mildly reduced, preserved, and improved ejection fraction, each with specific LVEF thresholds.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Francesco Cosentino et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF

Felipe A. Martinez et al.

CIRCULATION (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

Biswajit Chowdhury et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients

In-Chang Hwang et al.

CARDIOVASCULAR DIABETOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

Alexander J. M. Brown et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Petar M. Seferovic et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Heart Failure With Recovered Left Ventricular Ejection Fraction JACC Scientific Expert Panel

Jane E. Wilcox et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients - A Randomized Controlled Trial -

Hiroyuki Kayano et al.

CIRCULATION JOURNAL (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Donato Cappetta et al.

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study

Neale D. Cohen et al.

INTERNAL MEDICINE JOURNAL (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

Carlos G. Santos-Gallego et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

Akira Sezai et al.

CARDIOVASCULAR DIABETOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients

Munemitsu Otagaki et al.

CARDIOVASCULAR DRUGS AND THERAPY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial

Subodh Verma et al.

CIRCULATION (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial

Michael E. Nassif et al.

CIRCULATION (2019)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus

Jung-Chi Hsu et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Review Endocrinology & Metabolism

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Subodh Verma et al.

DIABETOLOGIA (2018)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Prognostic role of left ventricular ejection fraction in heart failure: Back to the future?

Giuseppe Ambrosio et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Fumitaka Soga et al.

CARDIOVASCULAR DIABETOLOGY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Shusuke Yagi et al.

DIABETOLOGY & METABOLIC SYNDROME (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes

Nadjib Hammoudi et al.

CARDIOVASCULAR DRUGS AND THERAPY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Michael Joubert et al.

DIABETES (2017)

添加到收藏夹

Article Endocrinology & Metabolism

CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis

Ele Ferrannini et al.

DIABETES CARE (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Sherif F. Nagueh et al.

JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2016)

添加到收藏夹

Correction Cardiac & Cardiovascular Systems

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging (vol 16, pg 233, 2015)

Lang

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging

Jens-Uwe Voigt et al.

JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Roberto M. Lang et al.

JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial

Journal of the American Heart Association (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Novel Predictors of Left Ventricular Reverse Remodeling in Individuals With Recent-Onset Dilated Cardiomyopathy

Milos Kubanek et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Left Ventricular Structural Remodeling in Health and Disease With Special Emphasis on Volume, Mass, and Geometry

William H. Gaasch et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prevalence and Prognostic Significance of Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy Receiving Tailored Medical Treatment

Marco Merlo et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Left Ventricular Remodeling in Heart Failure Current Concepts in Clinical Significance and Assessment

Marvin A. Konstam et al.

JACC-CARDIOVASCULAR IMAGING (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Presence of Extensive LV Remodeling Limits the Benefits of CRT in Patients With Intraventricular Dyssynchrony

Erberto Carluccio et al.

JACC-CARDIOVASCULAR IMAGING (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample - The framingham heart study

Guido A. Rosito et al.

CIRCULATION (2008)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events

David A. Bluemke et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

J Mathew et al.

CIRCULATION (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.